Status:
COMPLETED
Frequency of Hyperparathyroidism in Postmenopausal Osteoporosis and Its Treatment
Lead Sponsor:
Hospital Regional 1o de Octubre
Collaborating Sponsors:
Universidad Nacional Autonoma de Mexico
National Polytechnic Institute, Mexico
Conditions:
Postmenopausal Osteoporosis
Postmenopause
Eligibility:
FEMALE
Phase:
NA
Brief Summary
Recently, an increase in the prevalence of hyperparathyroidism and hypovitaminosis D in postmenopause women has been occurring in Mexico and the world. Chronic exposure to the parathyroid hormone (PTH...
Detailed Description
This study was an open clinical trial conducted in Mexican women diagnosed with postmenopausal osteoporosis and hyperparathyroidism associated or not with hypovitaminosis D from the climacteric clinic...
Eligibility Criteria
Inclusion
- Acceptance to participate in the study with informed consent.
- Postmenopausal osteoporosis or osteopenia.
- Primary or secondary hyperparathyroidism.
- Insufficiency or deficiency of vitamin D.
- Multi-treated postmenopausal osteoporosis.
- Postmenopausal osteoporosis without treatment.
Exclusion
- Different osteoporosis aetiology not related to oestrogenic deficiency.
- Thyroid pathology.
- Previous treatment with vitamin D, thiazide diuretics, lithium, Teriparatide or glucocorticoids.
- Known allergies to vitamin D.
- Addison's disease, pheochromocytoma, and depressive disorders.
Key Trial Info
Start Date :
April 29 2021
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 20 2022
Estimated Enrollment :
47 Patients enrolled
Trial Details
Trial ID
NCT05347082
Start Date
April 29 2021
End Date
February 20 2022
Last Update
May 6 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Peri-postmenopause and bone metabolism clinic. Regional Hospital October 1st ISSSTE
Mexico City, Mexico, 07300